{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 19:47:41", "close_timestamp": 1638902861755, "created": "07/12/2021 18:47:43", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "7d89d204-ccf6-4047-b816-b2ac8d7bf193", "open_date_time": "2021-11-7 19:38:57", "open_timestamp": 1638902337586, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "This story refers to a scientific study performed on the substance 'Ivermectin' at Monash University, by a team led by Dr Kylie Wagstaff. The research indicates that Ivermectin is able to kill the COVID-19 virus within 48 hours.", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 524169, "what": "This story reports a research performed on the substance 'Ivermectin' by Dr Kylie Wagstaff with Monash University.", "when_happened": "few_years_ago", "where_location": "Monash University", "who": "COVID-19, Dr Kylie Wagstaff, Ivermectin", "why": "The story is important because at that time the vaccines were scarcely available and there was, and still is, a need for substances that can stop the spread and kill the COVID-19 virus and its emerging variants."}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 20:4:8", "close_timestamp": 1638903848764, "created": "07/12/2021 19:04:10", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "bbda88f7-11a5-4513-bf67-af1be762b705", "open_date_time": "2021-11-7 19:56:20", "open_timestamp": 1638903380031, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax' COVID-19 vaccine in USA", "summary": "Novavax reports on the efficacy of its COVID-19 vaccine. The study has been performed on a big control group across two countries and reports high effectiveness rates however, it isn't certain how it might perform with new variants of the virus.", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 468733, "what": "The story describes the efficacy of a particular COVID-19 vaccine, and where it's going from there.", "when_happened": "current_month", "where_location": "The story took place across the US and Mexico, and also mentions India.", "who": "Novavax, COVID-19", "why": "Again, the story is important as the profits made by few on COVID-19 vaccines seem immoral and there are alternatives needed to be supplied worldwide."}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 19:56:9", "close_timestamp": 1638903369151, "created": "07/12/2021 18:56:10", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "b360b7ab-e213-4a0c-9392-e5dd4416e01c", "open_date_time": "2021-11-7 19:47:50", "open_timestamp": 1638902870953, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Medical Doctor Thomas Borody speaks out on Ivermectin therapy for COVID-19. He rationalizes why the therapy is effective and safe and why it could be used to treat COVID-19 before there are vaccinations available.", "task_condition": "text", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 498198, "what": "This story refers to the reader the view of one Thomas Borody, a successful medical doctor, on Ivermectin therapy targeting COVID-19.", "when_happened": "few_years_ago", "where_location": "in Australia.", "who": "Thomas Borody, COVID-19, Ivermectin", "why": "This story is important in my regard because the most popular COVID-19 vaccines, with the highest effectiveness rate reported are protected by a patent and cannot be used everywhere in the world, so any alternative way to combat the virus is vital."}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 19:38:35", "close_timestamp": 1638902315805, "created": "07/12/2021 18:38:37", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "6a7bcbaf-a120-4285-9d0f-6b6dae8334d0", "open_date_time": "2021-11-7 19:30:46", "open_timestamp": 1638901846514, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "On 21st of July 2020 Government of Japan approved the use of an immuno- boosting cocktail called 'Ronapreve' for its public. the cocktail targets spread and severity of COVID-19 and it's emerging variants.", "task_condition": "viz", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 469291, "what": "The story is about a particular cocktail of immuno-boosting substances that prevent COVID-19 being introduced in Japan.", "when_happened": "few_years_ago", "where_location": "in Japan.", "who": "The Government of Japan, COVID-19", "why": "new ways of preventing the spread and deaths caused by COVID-19"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 20:29:16", "close_timestamp": 1638905356714, "created": "07/12/2021 19:29:18", "department": "Computing", "disability": false, "ease": 4, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "34fc27fd-66f2-43e1-a893-87cd9855bbee", "open_date_time": "2021-11-7 20:18:49", "open_timestamp": 1638904729617, "summary": "I struggle to find the Pfizer corporation as a hero in the COVID-19 vaccinations story. Although the company's Comirnaty vaccine had the highest efficacy rate initially, it still hasn't proved to be effective against the newly emerging variants of the virus. And there is a question to be asked here: How does the pharmaceutical corporation profit from the virus? Is there business in rolling out the booster shot strategy? I think it's worth looking at how Pfizer and its investors benefit from having a patented vaccine shot being distributed across the US and European Union in the billions.", "task_condition": "text", "task_key": "pfizer", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 627097}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "GOLD_31", "age_group": "21_30", "agreed": true, "close_date_time": "2021-11-7 20:18:19", "close_timestamp": 1638904699101, "created": "07/12/2021 19:18:20", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-12-07", "gender": "other", "id": "b9105481-5e95-4df3-8d29-d95dec5d12b4", "open_date_time": "2021-11-7 20:4:19", "open_timestamp": 1638903859982, "summary": "AstraZeneca was a name that I haven't heard of before the pandemic began, and when it did, the race for the vaccine was something I was skeptical about. The vaccine rolled out by the corporation done in partnership with Oxford University was to be kept as a non-profit project until the pandemic ends, which is a noble cause, yet it seems hard to believe that a company would not profit in other ways from such massive contracts for hundreds of millions of doses with countries that are top players on the global scene. Even if the direct profits from the vaccine weren't gained, building a network so vast generates connections that will stay long after the vaccine rollout is complete. A giant uptick in the mentions of the company, even if not always positive (e.g. the blood-clot rumor proved to be false) will return a huge profit to the investors. ", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "under_graduate_year_2", "time_taken_in_seconds": 839119}}}